Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company

Genmab CEO Signals Potential for China Partnership as BioNTech Exits acasunlimab Collaboration

Fineline Cube Aug 20, 2024

COPENHAGEN—In a strategic pivot following BioNTech (NASDAQ: BNTX)’s withdrawal from their co-development partnership on the...

Company Drug

Hasten Biopharmaceutical Gains NMPA Nod for Somatostatin Marketing Rights in China

Fineline Cube Aug 20, 2024

BEIJING—Hasten Biopharmaceutical Co., Ltd, a biopharmaceutical company supported by the CBC Group, has received approval...

Company Drug

Yipinhong Pharmacy’s AR882 Earns FDA Fast-Track Status for Gout Treatment

Fineline Cube Aug 20, 2024

BEIJING—China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced that its novel drug AR882 has...

Company Deals

Sichuan Kelun Pharmaceutical’s H1 2024 Report Highlights MSD Collaboration Milestones

Fineline Cube Aug 20, 2024

CHENGDU—Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has released its financial report for the first...

Policy / Regulatory

NHSA Flags Concerns Over Pricing of MicroPort’s Castor Aortic Stent Graft System

Fineline Cube Aug 20, 2024

BEIJING—The National Healthcare Security Administration (NHSA) has issued an open letter expressing concerns over the...

Company Drug

Astellas Pharma’s Padcev Receives NMPA Approval for Urothelial Cancer Treatment

Fineline Cube Aug 20, 2024

TOKYO—Astellas Pharma Inc. (TYO: 4503) has announced that its anti-HER3 antibody-drug conjugate (ADC), Padcev (enfortumab...

Company Drug

BioNTech’s BNT326/YL202 Clears FDA Hurdle, Advancing in Clinical Trials for Solid Tumor Treatment

Fineline Cube Aug 20, 2024

FRANKFURT—BioNTech SE (NASDAQ: BNTX), a leading German biotechnology company, has announced that the US Food...

Company Deals

Jiangsu Hengrui Pharmaceuticals Expands R&D Footprint with Jinan Innovation Zone Partnership

Fineline Cube Aug 20, 2024

JINAN—The management committee of the Jinan Innovation Zone has entered into a strategic partnership with...

Company Medical Device

China’s NMPA Grants Medical Device License to DaAn Gene’s Monkeypox Detection Kit

Fineline Cube Aug 20, 2024

GUANGZHOU—DaAn Gene Co., Ltd, a subsidiary of Sun Yat-sen University based in China (SHE: 002030),...

Company Deals

Genesis MedTech’s J-VALVE System Transfers to Edwards Lifesciences, Marking a New Era in Aortic Valve Treatment

Fineline Cube Aug 20, 2024

SINGAPORE—In a strategic move to strengthen its position in the global medical device market, Edwards...

Company Drug

Changchun High & New Technology Secures NMPA Approval for Turner Syndrome Treatment

Fineline Cube Aug 20, 2024

CHANGCHUN—Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading biopharmaceutical company in...

Company Drug

AstraZeneca’s Fasenra Secures NMPA Approval for Severe Eosinophilic Asthma Maintenance Therapy

Fineline Cube Aug 20, 2024

BEIJING—The National Medical Products Administration (NMPA) of China has granted market approval for AstraZeneca (NASDAQ:...

Company Drug

Genmab’s Tepkinly/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments

Fineline Cube Aug 20, 2024

COPENHAGEN—Genmab A/S (NASDAQ: GMAB), a leading biotech company, has announced that the European Commission (EC)...

Company Deals

Multitude Therapeutics and Adcendo ApS Partner on Anti-TF ADC, Targeting Global Cancer Treatment

Fineline Cube Aug 20, 2024

SHANGHAI/COPENHAGEN—In a strategic move to bolster cancer treatment options, Shanghai-based medical technology company Multitude Therapeutics...

Company Medical Device

Lepu Medical Secures Approval for RECATCHOR Catheter, Enhancing Cardiovascular Procedures

Fineline Cube Aug 19, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...

Drug Policy / Regulatory

Beijing Proposes New Regulations to Enhance Pharmaceutical Retail Standards and Services

Fineline Cube Aug 19, 2024

The Beijing Municipal Medical Products Administration has unveiled a draft proposal titled “Guiding Opinions on...

Company Drug

AstraZeneca’s Imfinzi Gains FDA Approval for Neoadjuvant Use in Early-Stage Lung Cancer

Fineline Cube Aug 19, 2024

AstraZeneca (NASDAQ: AZN, LON: AZN) , the UK-based pharmaceutical powerhouse, has secured US FDA approval...

Company

RemeGen Reports 75.6% Revenue Surge in H1 2024, Driven by Key Product Sales

Fineline Cube Aug 19, 2024

RemeGen (HKG: 9995) has reported a robust performance in its first half of 2024, achieving...

Company Medical Device

Robotrak Secures NMPA License for China’s First Smart Ophthalmic Navigation Laser

Fineline Cube Aug 19, 2024

Robotrak, a Nanjing-based ophthalmic innovation platform, has secured a Category III medical device license from...

Company Drug

Sichuan Biokin Launches Phase III Trial for Bispecific ADC BL-B01D1 in Lung Cancer

Fineline Cube Aug 19, 2024

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has commenced the first patient dosing in a...

Posts pagination

1 … 364 365 366 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.